- Home
- RARE vs ALHC Comparison
RARE vs ALHC Comparison
Compare RARE & ALHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- ALHC
- Stock Information
- Founded
- RARE 2010
- ALHC 2013
- Country
- RARE United States
- ALHC United States
- Employees
- RARE N/A
- ALHC N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- ALHC Medical Specialities
- Sector
- RARE Health Care
- ALHC Health Care
- Exchange
- RARE Nasdaq
- ALHC Nasdaq
- Market Cap
- RARE 2.6B
- ALHC 2.7B
- IPO Year
- RARE 2014
- ALHC 2021
- Fundamental
- Price
- RARE $29.96
- ALHC $16.36
- Analyst Decision
- RARE Strong Buy
- ALHC Buy
- Analyst Count
- RARE 14
- ALHC 11
- Target Price
- RARE $86.64
- ALHC $18.14
- AVG Volume (30 Days)
- RARE 1.4M
- ALHC 2.9M
- Earning Date
- RARE 08-05-2025
- ALHC 10-28-2025
- Dividend Yield
- RARE N/A
- ALHC N/A
- EPS Growth
- RARE N/A
- ALHC N/A
- EPS
- RARE N/A
- ALHC N/A
- Revenue
- RARE $610,159,000.00
- ALHC $3,335,894,000.00
- Revenue This Year
- RARE $19.72
- ALHC $47.18
- Revenue Next Year
- RARE $23.29
- ALHC $28.45
- P/E Ratio
- RARE N/A
- ALHC N/A
- Revenue Growth
- RARE 26.77
- ALHC 49.46
- 52 Week Low
- RARE $25.81
- ALHC $8.65
- 52 Week High
- RARE $60.37
- ALHC $21.06
- Technical
- Relative Strength Index (RSI)
- RARE 53.11
- ALHC 71.28
- Support Level
- RARE $29.04
- ALHC $15.38
- Resistance Level
- RARE $30.61
- ALHC $16.52
- Average True Range (ATR)
- RARE 0.80
- ALHC 0.54
- MACD
- RARE 0.31
- ALHC 0.13
- Stochastic Oscillator
- RARE 79.81
- ALHC 92.38
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.